Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Overview | Financials
Company Name Syndax Pharmaceuticals, Inc.
Symbol SNDX
Currency USD
Price 19.1
Market Cap 1,625,341,240
Dividend Yield 0%
52-week-range 11.215 - 25.34
Industry Biotechnology
Sector Healthcare
CEO Mr. Michael A. Metzger M.B.A.
Website https://www.syndax.com

An error occurred while fetching data.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant

Related Stocks

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

52.51 USD

REGENXBIO Inc. logo

REGENXBIO Inc.

RGNX

11.48 USD

National Research Corporation logo

National Research Corporation

NRC

21.71 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

41.12 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

5.04 USD

Morphic Holding, Inc. logo

Morphic Holding, Inc.

MORF

56.99 USD

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

11.54 USD

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

1.17 USD

Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc.

TMCI

5.33 USD

Financials

Numbers are in millions USD

Numbers are in millions USD